证券之星消息，截至2025年9月5日收盘，开立医疗(300633)报收于32.33元，上涨2.31%，换手率 0.72%，成交量3.12万手，成交额1.0亿元。 该股主要指标及行业内排名如下： | 指标 | 开立医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 139.9亿元 | 119.33亿元 | 25 123 | | 净资产 | 31.16亿元 | 38.89亿元 | 47 123 | | 净利润 | 4703.03万元 | 1.49亿元 | 60 123 | | 市盈率(动) | 148.73 | 65.4 | 81 123 | | 市净率 | 4.49 | 3.87 | 95 123 | | 毛利率 | 62.08% | 51.85% | 50 123 | | 净利率 | 4.88% | 10.39% | 84 123 | | ROE | 1.5% | 1.8% | 75 123 | 9月5日的资金流向数据方面，主力资金净流出158.51万元，占总成交额1.58%，游资资金净流入286.29 万元，占总成交额2.86%，散户资金净流出1 ...

证券之星消息，截至2025年9月4日收盘，开立医疗(300633)报收于31.6元，下跌1.31%，换手率0.94%， 成交量4.05万手，成交额1.29亿元。 9月4日的资金流向数据方面，主力资金净流出1350.51万元，占总成交额10.47%，游资资金净流出 171.51万元，占总成交额1.33%，散户资金净流入1522.02万元，占总成交额11.8%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-04 | 31.60 | -1.31% | -1350.51万 | -10.47% | -171.51万 | -1.33% | 1522.02万 | - 11.80% | | 2025-09-03 | 32.02 | -2.44% | -188.16万 | -1.84% | 159.43万 | 1.56% | 28.73万 | 0.28% | | 2025-09-02 | 32 ...

Core Viewpoint - The stock of Kaili Medical (300633) has experienced a decline, with significant net outflows from major funds, indicating potential concerns among institutional investors [1][2]. Financial Performance - As of August 27, 2025, Kaili Medical's stock closed at 32.93 yuan, down 2.75% with a trading volume of 82,500 lots and a turnover of 276 million yuan [1]. - The company reported a main revenue of 964 million yuan for the first half of 2025, a year-on-year decrease of 4.78%, and a net profit attributable to shareholders of 47.03 million yuan, down 72.43% year-on-year [3]. - The second quarter of 2025 saw a main revenue of 534 million yuan, a slight increase of 0.17% year-on-year, but the net profit decreased by 44.65% to 38.96 million yuan [3]. Market Position and Ratios - Kaili Medical's total market capitalization is 14.249 billion yuan, with a net asset value of 3.116 billion yuan, and a net profit of 47.03 million yuan, ranking 58th in the medical device industry [3]. - The company's price-to-earnings ratio (P/E) stands at 151.49, significantly higher than the industry average of 73.16, indicating a potential overvaluation [3]. - The gross margin is reported at 62.08%, which is above the industry average of 51.64%, while the net margin is at 4.88%, below the industry average of 11.01% [3]. Fund Flow Analysis - On August 27, 2025, the net outflow of major funds was 14.89 million yuan, accounting for 5.4% of the total turnover, while retail investors saw a net inflow of 782,300 yuan, representing 0.28% of the total turnover [1][2]. - Over the past five days, the stock has seen fluctuating fund flows, with significant net outflows from major funds on multiple days, indicating a trend of institutional selling [2]. Analyst Ratings - In the last 90 days, 15 institutions have rated the stock, with 12 buy ratings and 3 hold ratings, suggesting a generally positive outlook despite recent performance [4]. - The average target price set by analysts over the past 90 days is 42.65 yuan, indicating potential upside from the current trading price [4].

证券之星消息，截至2025年8月21日收盘，开立医疗(300633)报收于35.65元，上涨3.36%，换手率 2.06%，成交量8.91万手，成交额3.18亿元。 8月21日的资金流向数据方面，主力资金净流入1872.8万元，占总成交额5.88%，游资资金净流出524.04 万元，占总成交额1.65%，散户资金净流出1348.76万元，占总成交额4.24%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-21 | 35.65 | 3.36% | 1872.80万 | 5.88% | -524.04万 | -1.65% | -1348.76万 | -4.24% | | 2025-08-20 | | 34.49 -0.32% | -1197.81万 | -10.50% | 238.58万 | 2.09% | 959.23万 | 8.41% | | 2025-08-19 | | 3 ...

Financial Performance - For the first half of 2025, the company's operating revenue was approximately 964.26 million yuan, a decrease from 1,012.69 million yuan in the same period last year, representing a decline of about 4.78% [1] - The net profit attributable to shareholders was approximately 47.03 million yuan, down from 170.57 million yuan year-on-year, indicating a significant drop of about 72.49% [1] - The net profit after deducting non-recurring gains and losses was approximately 39.88 million yuan, compared to 154.94 million yuan in the previous year, a decrease of about 74.30% [1] - The basic earnings per share were 0.1087 yuan, down from 0.3956 yuan year-on-year [1] - The weighted average return on equity was 1.50%, a decline of 3.80 percentage points compared to the previous year [19] Cash Flow and Assets - The net cash flow from operating activities was -250.30 million yuan, a decrease of 265 million yuan compared to the previous year [22] - Total assets at the end of the reporting period were approximately 4,017.77 million yuan, down from 4,312.99 million yuan at the end of the previous year [1] - The company experienced a 99.66% decrease in trading financial assets compared to the end of the previous year, while inventory increased by 20.61% [34] Shareholder Structure - As of the end of the first half of 2025, the top ten shareholders included a new shareholder, Guangfa High-end Manufacturing Equity Fund, replacing the previous quarter's shareholder [51] - The Social Security Fund 17022 portfolio and several healthcare-focused funds increased their holdings [51] Valuation Metrics - As of August 21, the company's price-to-earnings ratio (TTM) was approximately 818.18 times, the price-to-book ratio (LF) was about 4.95 times, and the price-to-sales ratio (TTM) was around 7.85 times [1]

Core Insights - The core viewpoint of the news is that Kaili Medical has experienced a significant decline in its operating performance in the first half of 2025, with indications of a potential recovery in the second quarter. Financial Performance - In the first half of 2025, Kaili Medical reported operating revenue of 964 million yuan, a year-on-year decrease of 4.78% [1] - The net profit attributable to shareholders was 47 million yuan, a substantial year-on-year decline of 72.43% [1] - The second quarter net profit attributable to shareholders was 39 million yuan, showing a significant quarter-on-quarter increase of 382.45% [1] Profitability Indicators - The net profit margin dropped from 16.84% in the first half of 2024 to 4.88% in 2025 [3] - The gross profit margin decreased from 67.43% to 62.08% [3] - The return on equity fell by 3.80 percentage points to 1.50% [3] Operational Stability - Kaili Medical faced inventory management pressures, with inventory turnover days reaching 354.68 days, an increase of 46.46% year-on-year [5] - The net cash flow from operating activities was -250 million yuan, a shift from a positive 15 million yuan in the same period of 2024 [5] - The asset-liability ratio for the first half of 2025 was 22.46%, a year-on-year decrease of 1.23 percentage points, indicating better control over debt levels [5] Institutional Holdings - As of the first half of 2025, the number of institutions holding Kaili Medical's stock was 32, a significant decrease of 312 from 344 in the same period of 2024 [8] - The highest market capitalization of Kaili Medical was 26.967 billion yuan on June 9, 2023, while the current market capitalization is 15.426 billion yuan, indicating a required stock price increase of 74.82% to reach the historical peak [8] - Despite the challenges, the stock price has increased by 21.67% year-to-date, reflecting some market confidence in the company's long-term prospects [8]

证券之星消息，截至2025年8月20日收盘，开立医疗(300633)报收于34.49元，下跌0.32%，换手率 0.77%，成交量3.33万手，成交额1.14亿元。 8月20日的资金流向数据方面，主力资金净流出1197.81万元，占总成交额10.5%，游资资金净流入 238.58万元，占总成交额2.09%，散户资金净流入959.23万元，占总成交额8.41%。 近5日资金流向一览见下表： | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-20 | 34.49 -0.32% | -1197.81万 | -10.50% | 238.58万 | 2.09% | 959.23万 | - 8.41% | | 2025-08-19 | 34.60 1.05% | -102.65万 | -0.56% | -543.79万 | -2.96% | 646.44万 | 3.52% | | 2025-08-18 | 34.24 -0.52% | ...